A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

Study Location:

Baltimore

Topic:

HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02128217?term=a5327&rank=1

IRB#:

NA_00093365

Coordinator:

Anna Wimpelberg (Washington)

​Ilene Wiggins, RN (Baltimore)
 

Enrollment:

Closed

Trial Period:

Completed

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1 positive subjects will be enrolled and administered oral sofosbuvir (SOF) in combination with weight-based ribavirin (RBV).

Men and women > 18 years, HIV+ and currently on stable antiretroviral (ARV) medications or on for at least 8 weeks and be newly infected (within the last 6 months) or recently re-infected with hepatitis C.

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More